Roche's Xeloda Shows Significant Survival Benefit In Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Combo therapy of Xeloda plus gemcitabine shows median survival of 7.4 months versus six months with Gemzar alone.
You may also be interested in...
Xeloda Stomach Cancer Filing Will Likely Reach EU Before FDA, Roche Says
A pivotal trial found Xeloda in combination with cisplatin was non-inferior to the current standard-of-care for advanced gastric cancer, firm says.
Xeloda Stomach Cancer Filing Will Likely Reach EU Before FDA, Roche Says
A pivotal trial found Xeloda in combination with cisplatin was non-inferior to the current standard-of-care for advanced gastric cancer, firm says.
FDA Approves Tarceva For Pancreatic Cancer
Supplemental NDA approval for Genentech/OSI’s erlotinib, previously approved for lung cancer, follows advisory committee recommendation.